Non-myeloablative tolerogenic treatment

(19)

(11)

EP 1 498 136 A8

(12)	CORRECTED EUROPEAN PATENT APPLICATION

(48)	Corrigendum issued on:
	13.04.2005 Bulletin 2005/15

(43)	Date of publication:
	19.01.2005 Bulletin 2005/03

(21)	Application number: 04024995.5

(22)	Date of filing: 23.12.1999

(51)	International Patent Classification (IPC)⁷: A61K 39/00, A61K 35/14, A61K 35/28, A61P 35/00

(84)	Designated Contracting States:
	AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

(30)

Priority:

31.12.1998 US 222011

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	99968946.6 / 1141246

(71)	Applicants:
	HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. 91120 Jerusalem (IL) BAXTER INTERNATIONAL INC. Deerfield, IL 60015 (US)

(72)	Inventors:
	Slavin, Shimon Ein Karem, Jerusalem (IL) Prigozhina, Tatyana Rehovot (IL)

(74)	Representative: Schmitz, Jean-Marie
	Dennemeyer & Associates S.A. P.O. Box 1502 1015 Luxembourg 1015 Luxembourg (LU)


	Remarks:
	This application was filed on 22 - 10 - 2004 as a divisional application to the application mentioned under INID code 62.

(54)	Non-myeloablative tolerogenic treatment

(57) The present invention relates to the use of antigens of a donor mammal in the manufacture of a medicament for inducing tolerance in a host mammal to a graft from said donor mammal, said donor mammal being non-syngeneic to said host mammal, wherein:

(a) said antigens are administered to said host mammal:
(b) an immunosuppressive agent is administered to said host mammal in a non-myeloablative regimen sufficient to decrease said host mammal's functional T-lymphocyte population;
(c) said graft is transplanted into said host mammal, wherein steps (a), (b) and (c) are performed on the same day; and
(d) a non-myeloablative dose of lymphocytotoxic or tolerizing agent is administered to said host mammal to selectively eliminate said host mammal's lymphocytes responding to said antigens.